Search results for "AGENT"

showing 10 items of 8904 documents

Incretin-based therapies in 2021 – Current status and perspectives for the future

2021

medicine.medical_specialtyDipeptidyl-Peptidase IV Inhibitorsbusiness.industryEndocrinology Diabetes and MetabolismMEDLINEIncretinDiabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents IncretinsIncretinsGlucagon-Like Peptide-1 ReceptorArticleEndocrinologyDiabetes Mellitus Type 2Internal medicinemedicineHumansHypoglycemic AgentsCurrent (fluid)Intensive care medicinebusiness
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

2018

Abstract Fibrates are drugs that reduce triglycerides, elevate high-density lipoproteins, as well as decrease small, dense LDL particles. The results of a study have recently been published by the Cochrane Collaboration on fibrates efficacy and safety in the primary prevention of cardiovascular disease. This study includes a systematic review and a meta-analysis of 6 studies (16,135 patients) that evaluated the clinical benefits of fibrates compared to placebo use or other lipid-lowering drugs. This review showed evidence of a protective effect of the fibrates compared with placebo as regards a reduction 16% of a compound objective of death due to cardiovascular disease, non-fatal myocardia…

medicine.medical_specialtyDiseasePlacebochemistry.chemical_compoundInternal medicinePrimary preventionmedicineHumansMyocardial infarctionHypolipidemic AgentsGeneral Environmental ScienceCreatinineCochrane collaborationbusiness.industryFibric AcidsGeneral EngineeringDiabetic retinopathymedicine.diseaseLipidsPrimary PreventionTotal mortalitychemistryCardiovascular DiseasesCreatinineGeneral Earth and Planetary SciencesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Will it ever become possible to prevent dopaminergic neuronal degeneration?

2008

Parkinsons disease (PD) is the second leading age-related degenerative brain disease in the world affecting millions of people. This neurological disorder disrupts the quality of life of patients and their families, exerts an enormous emotional and physical strain on caregivers, and has a large cost for society. Moreover, the increasing numbers of elderly people in the population will result in a sharp increase in the prevalence of PD. The understanding of its pathophysiology and treatment has advanced at a very impressive rate during past decades. Nevertheless, PD is still fatal and there is at present no cure for it. Furthermore, there are no proven therapies for prevention of PD and alth…

medicine.medical_specialtyDopaminePopulationNeurological disorderDiseaseNeuroprotectionSettore BIO/09 - FisiologiaNeuroprotective agentsRisk FactorsmedicineAnimalsHumansNeuronal degenerationNeurodegeneration Neuroprotection Parkinson's diseaseIntensive care medicineeducationPharmacologyNeuronseducation.field_of_studyCell Deathbusiness.industryGeneral NeuroscienceDopaminergicNeurodegenerative DiseasesParkinson's disease -- Treatmentmedicine.diseaseBrain diseaseNeuroprotective AgentsDrug developmentbusinessNervous system -- Degeneration
researchProduct

Compounded preparations in dermatology – analysis of prescribing habits in everyday clinical practice in Germany

2020

Background Compounded preparations (CPs) are an indispensable addition to approved, commercially available drugs (CADs), especially for topical therapy. In Germany, about eight million CPs are prescribed within the statutory health insurance system each year, 50 % thereof by dermatologists. Methods We analyzed prescribing habits based on a questionnaire sent out to 186 office-based dermatologists and 1,491 pharmacies in the federal states of Rhineland-Palatinate and Saarland. The goal was to improve patient care by collecting and categorizing data in terms of prescription practice and associated challenges in interdisciplinary cooperation. Results Overall, 351 pharmacists (23.5 %) and 53 de…

medicine.medical_specialtyDrug CompoundingMEDLINEContext (language use)PharmacyDermatologyPharmacistsSkin Diseases030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineContinuing medical educationGermanySurveys and QuestionnairesHumansMedicinePractice Patterns Physicians'Medical prescriptionPharmaciesbusiness.industryCompounded preparationsTopical medicationClinical PracticeCross-Sectional StudiesFamily medicineDermatologic AgentsbusinessDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

The use of same in chemotherapy-induced liver injury

2018

Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs most frequently associated with idiosyncratic DILI. For this reason, patients who receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate and which drug doses should be modified. S-adenosylmethionine (SAMe) is an endogenous agent derived from methionine. Its supplementation is effective in the treatment of liver disease, in particular intrahepatic cholestasis (IHC). The target of this review is to analyze the mechanisms of hepatotoxicity of the principal antican…

medicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsDrug-induced liver injurySettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineCholestasisChemotherapy inducedInternal medicineNeoplasmsmedicineAnimalsHumansChemotherapyLiver injuryChemotherapyS-adenosylmethioninebusiness.industryHepatotoxicityHematologymedicine.diseaseOncologyCholestasi030220 oncology & carcinogenesisImmunohistochemistry030211 gastroenterology & hepatologyChemotherapy; Cholestasis; Drug-induced liver injury; Hepatotoxicity; S-adenosylmethionine; Hematology; OncologyLiver functionChemical and Drug Induced Liver InjuryComplicationbusiness
researchProduct

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

2015

PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse events. This spectrum is different from toxicities known for kinase inhibitors or cytotoxic drugs. Since PD-1 directed therapies show effectivity in an increasing number of malignant diseases, their clinical usage will increase rapidly. Therefore clinicians from different specialities such as medical oncology, internal medicine, family doctors and emergency unit staff should be aware of the adverse effects of PD-1 checkpoint inhibitors to avoid delays in diagnosis and treatment. Based on pooled data from pivotal trials as reported by the European Medicines Agency, the present paper reviews incidence…

medicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMedizinAntineoplastic AgentsPembrolizumabAntibodies Monoclonal HumanizedB7-H1 Antigen03 medical and health sciences0302 clinical medicineRefractoryMonitoring ImmunologicNeoplasmsmedicineEndocrine systemHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineAdverse effectbusiness.industryAntibodies MonoclonalDisease ManagementGeneral MedicineImmunotherapymedicine.diseaseEarly DiagnosisNivolumabOncologyMethylprednisolone030220 oncology & carcinogenesisImmunologyNivolumabbusinessAdverse drug reactionImmunosuppressive Agentsmedicine.drugCancer treatment reviews
researchProduct

Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction: a systematic revi…

2016

Background: Prophylactic use of amoxicillin and amoxicillin/clavulanic acid, although controversial, is common in routine clinical practice in third molar surgery. Material and Methods: Our objective was to assess the efficacy of prophylactic amoxicillin with or without clavulanic acid in reducing the incidence of dry socket and/or infection after third molar extraction. We conducted a systematic review and meta-analysis consulting electronic databases and references in retrieved articles. We included double-blind placebo-controlled randomized clinical trials published up to June 2015 investigating the efficacy of amoxicillin with or without clavulanic acid on the incidence of the aforement…

medicine.medical_specialtyDry SocketOdontologíaReviewTooth ExfoliationPlaceboAmoxicillin-Potassium Clavulanate Combinationlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawClavulanic acidInternal medicinemedicineHumansGeneral DentistryInfection Control030219 obstetrics & reproductive medicineAmoxicillin/clavulanic acidbusiness.industryAmoxicillin030206 dentistryAmoxicillinmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryAnti-Bacterial AgentsDry socketOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASNumber needed to treatSurgeryMolar ThirdAmoxicillin-Potassium Clavulanate CombinationOral Surgerybusinessmedicine.drug
researchProduct

Chronic oral haloperidol and clozapine in rats: A behavioral evaluation.

1999

The present study evaluated chronic oral treatment of rats with haloperidol or clozapine. Drugs were given in the drinking water for a 23-day period . Rat behavior was analyzed once a week in an open field. Rats ingested either 1.7 mg/kg haloperidol or 40 mg/kg clozapine daily. Blood serum analysis revealed concentrations of 6 ng/ml for haloperidol and 22 ng/ml for clozapine at the end of the treatment. Haloperidol decreased overall activity from the onset of treatment. Clozapine showed similar effects only on the last test day. Control animals showed a slight habituation in exploration-related parameters. In conclusion, these results indicate that oral drug administration through the drink…

medicine.medical_specialtyDyskinesia Drug-InducedTime FactorsAdministration OralPharmacologyWeight GainOpen fieldRats Sprague-DawleyBlood serumOral administrationInternal medicinemedicineHaloperidolAnimalsHabituationHabituation PsychophysiologicClozapineBiological PsychiatryClozapineAnalysis of VarianceBehavior Animalbusiness.industryAntagonistRatsPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologyExploratory BehaviorHaloperidolFemaleAnalysis of variancebusinessLocomotionmedicine.drugAntipsychotic AgentsNeuropsychobiology
researchProduct

Complications of botulinum toxin and fillers: A narrative review

2019

Background Cosmetic surgery and esthetic procedures have become a billion dollar industry owing to the ever-growing demand of the population to stay young. The injectable treatments including fillers and botulinum toxin have become highly popular because of their quick, predictable and lasting results in the management of facial wrinkles and rejuvenation. Although these treatment modalities are relatively safe, they are associated with certain side effects. Aims In this review, we will focus on the complications of fillers and botulinum toxin. Patients/methods The literature research considered published journal articles (clinical trials or scientific reviews). Studies were identified by se…

medicine.medical_specialtyEcchymosisPopulationMEDLINEFacial MusclesCosmetic TechniquesDermatologyPain ProceduralInjections030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDermal FillersHumansMedicineBotulinum Toxins Type AeducationIntensive care medicineAdverse effecteducation.field_of_studybusiness.industryBotulinum toxinInjection Site ReactionClinical trialFacial AsymmetryNeuromuscular Agents030220 oncology & carcinogenesisBrow ptosisNarrative reviewEyebrowsmedicine.symptombusinessmedicine.drugJournal of Cosmetic Dermatology
researchProduct